로딩 중…
지수 로딩 중…
Viridian Therapeutics, Inc.
VRDN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$19.31+2.06%
2026-08-03
Financials
Valuation Metrics
Viridian Therapeutics, Inc.'s Market Cap is $2.13B. At end of 2025 it was $2.64B. Ranked #2006 of 3,112 in US market (top 64%), #759 of 1,445 on NASDAQ (top 53%), #128 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.13B | US#2,006/3,112 Sec#128/269 |
| Revenue | $71M | US#2,837/3,112 Sec#143/269 |
| Net Income | $-361M | US—/3,112 Sec—/269 |
| Total Assets | $789M | US#2,549/3,112 Sec#109/269 |
| Net Assets | $636M | US#2,085/3,112 Sec#89/269 |
| Value | ||
| P/B | 3.35x | US#1,803/3,112 Sec#104/269 |
| P/S | 30.07x | US#2,851/3,112 Sec#159/269 |
| FCF Yield | -14.25% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -56.70% | US#2,765/3,112 Sec#184/269 |
| ROA | -45.70% | US#2,951/3,112 Sec#206/269 |
| Op. Margin | -543.86% | US#2,897/3,112 Sec#162/269 |
| Revenue Growth | 95.83% | US#155/3,112 Sec#34/269 |
| Financial Health | ||
| Debt Ratio | 24.06% | US#257/3,112 Sec#84/269 |
| Total Debt | $51M | US#2,540/3,112 Sec#145/269 |
| FCF | $-304M | US#2,786/3,112 Sec#239/269 |
| Cash | $176M | US#1,813/3,112 Sec#125/269 |
| Current Ratio | 15.15x | US#161/3,112 Sec#50/269 |
| Performance | ||
| 1Y Return | 10.91% | US#1,623/3,112 Sec#172/269 |
| 1M Return | -0.46% | US#1,719/3,112 Sec#81/269 |
| From 52W High | -43.69% | US#2,637/3,112 Sec#205/269 |
| 1Y MDD | -60.63% | US#2,739/3,112 Sec#215/269 |
| Trading | ||
| Volume | 1,811,904 shares | US#972/3,112 Sec#89/269 |
| Trading Value | $34M | US#1,635/3,112 Sec#109/269 |
| Per Share | ||
| EPS | $-4.04 | US—/3,112 Sec—/269 |
| BPS | $8.52 | US#1,888/3,112 Sec#77/269 |